Payment overview · 2025
General Payments
$1,136.85
58 reported records · 11 companies
Healthcare provider profile · identity verified
James W Hansen, MD
Allopathic & Osteopathic Physicians|Internal Medicine · JOHNSON CITY, TN · NPI 1275531212
Verified facts
What the public records show
CMS Open Payments records show James W Hansen, MD received $1,136.85 in general payments during 2025 across 58 reported records.
AstraZeneca Pharmaceuticals LP accounted for 40.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 158 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 337 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $455.17 | 40.0% | 18 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $186.39 | 16.4% | 19 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $175.04 | 15.4% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $82.34 | 7.2% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $59.15 | 5.2% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $57.86 | 5.1% | 3 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $47.20 | 4.2% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.69 | 2.2% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.82 | 1.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $14.55 | 1.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.64 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $986.85 | 57 |
| Consulting Fee | $150.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $291.16 | 9 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $186.39 | 19 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $186.39 | 19 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $178.86 | 4 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $175.04 | 2 | 2025 |
Source payment records
|
|||||
| XYREM Normalized: xyrem |
Drug | JAZZ PHARMACEUTICALS INC. | $150.00 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $114.68 | 6 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $52.04 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $52.04 | 3 | 2025 |
Source payment records
|
|||||
| GIVLAARI Normalized: givlaari |
Drug | Alnylam Pharmaceuticals Inc. | $47.20 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $41.07 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $41.07 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $40.07 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $30.30 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $24.69 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $22.10 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $20.82 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $19.08 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.79 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $14.55 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $13.64 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $13.64 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $13.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 158 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 147 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 103 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 120 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 63 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
52 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
158 | 33 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
147 | 27 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
63 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
147 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
103 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
120 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
337 | 56 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 856 | 216 |
| Levothyroxine Sodium | Levothyroxine Sodium | 817 | 178 |
| Alprazolam | Alprazolam | 802 | 112 |
| Amlodipine Besylate | Amlodipine Besylate | 699 | 164 |
| Losartan Potassium | Losartan Potassium | 604 | 157 |
| Lisinopril | Lisinopril | 520 | 120 |
| Omeprazole | Omeprazole | 514 | 121 |
| Atorvastatin Calcium | Atorvastatin Calcium | 509 | 137 |
| Gabapentin | Gabapentin | 504 | 76 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 440 | 75 |
| Metformin Hcl | Metformin Hcl | 395 | 99 |
| Pantoprazole Sodium | Pantoprazole Sodium | 381 | 104 |
| Tramadol Hcl | Tramadol Hcl | 375 | 59 |
| Eliquis | Apixaban | 337 | 56 |
| Potassium Chloride | Potassium Chloride | 328 | 88 |
| Pregabalin | Pregabalin | 327 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 300 | 77 |
| Escitalopram Oxalate | Escitalopram Oxalate | 279 | 65 |
| Metoprolol Tartrate | Metoprolol Tartrate | 263 | 65 |
| Sertraline Hcl | Sertraline Hcl | 250 | 54 |
| Furosemide | Furosemide | 233 | 67 |
| Zolpidem Tartrate | Zolpidem Tartrate | 231 | 34 |
| Telmisartan | Telmisartan | 228 | 49 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 222 | 72 |
| Ezetimibe | Ezetimibe | 213 | 59 |
| Clopidogrel | Clopidogrel Bisulfate | 209 | 48 |
| Metoprolol Succinate | Metoprolol Succinate | 208 | 54 |
| Duloxetine Hcl | Duloxetine Hcl | 188 | 39 |
| Lorazepam | Lorazepam | 188 | 33 |
| Famotidine | Famotidine | 183 | 47 |
| Montelukast Sodium | Montelukast Sodium | 182 | 42 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 175 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 172 | 46 |
| Mirtazapine | Mirtazapine | 169 | 35 |
| Spironolactone | Spironolactone | 167 | 41 |
| Simvastatin | Simvastatin | 163 | 43 |
| Farxiga | Dapagliflozin Propanediol | 158 | 33 |
| Prednisone | Prednisone | 157 | 36 |
| Trazodone Hcl | Trazodone Hcl | 148 | 27 |
| Jardiance | Empagliflozin | 147 | 27 |
| Allopurinol | Allopurinol | 145 | 38 |
| Cefdinir | Cefdinir | 145 | 91 |
| Bupropion Xl | Bupropion Hcl | 138 | 28 |
| Alendronate Sodium | Alendronate Sodium | 137 | 27 |
| Chlorthalidone | Chlorthalidone | 133 | 36 |
| Finasteride | Finasteride | 133 | 31 |
| Meloxicam | Meloxicam | 132 | 35 |
| Temazepam | Temazepam | 124 | 20 |
| Celecoxib | Celecoxib | 123 | 24 |
| Ozempic | Semaglutide | 120 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 119 | 29 |
| Tizanidine Hcl | Tizanidine Hcl | 119 | 25 |
| Clonazepam | Clonazepam | 117 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 113 | 29 |
| Oxybutynin Chloride | Oxybutynin Chloride | 111 | 27 |
| Ondansetron Hcl | Ondansetron Hcl | 110 | 37 |
| Fluoxetine Hcl | Fluoxetine Hcl | 109 | 20 |
| Warfarin Sodium | Warfarin Sodium | 109 | 24 |
| Buspirone Hcl | Buspirone Hcl | 104 | 23 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 104 | 21 |
| Mounjaro | Tirzepatide | 103 | 19 |
| Metformin Hcl Er | Metformin Hcl | 102 | 29 |
| Methylprednisolone | Methylprednisolone | 102 | 67 |
| Repatha Sureclick | Evolocumab | 100 | 18 |
| Donepezil Hcl | Donepezil Hcl | 94 | 25 |
| Ropinirole Hcl | Ropinirole Hcl | 89 | 21 |
| Carvedilol | Carvedilol | 88 | 30 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 87 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 87 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 84 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 83 | 69 |
| Diazepam | Diazepam | 83 | 15 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 82 | 16 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 82 | 17 |
| Ondansetron Odt | Ondansetron | 79 | 21 |
| Tresiba Flextouch U-100 | Insulin Degludec | 77 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 76 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 74 | 17 |
| Atenolol | Atenolol | 73 | 20 |
| Nebivolol Hcl | Nebivolol Hcl | 73 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 72 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 70 | 25 |
| Ibuprofen | Ibuprofen | 68 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 66 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 63 | 16 |
| Ipratropium Bromide | Ipratropium Bromide | 63 | 20 |
| Memantine Hcl | Memantine Hcl | 63 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 63 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 60 | suppressed |
| Xarelto | Rivaroxaban | 60 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 59 | 12 |
| Methocarbamol | Methocarbamol | 59 | 16 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 58 | suppressed |
| Glipizide | Glipizide | 57 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 56 | 17 |
| Belsomra | Suvorexant | 55 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 55 | 32 |
| Creon | Lipase/Protease/Amylase | 52 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 51 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 51 | 13 |
| Fluconazole | Fluconazole | 50 | 28 |
| Humalog Kwikpen U-100 | Insulin Lispro | 48 | 12 |
| Promethazine Hcl | Promethazine Hcl | 47 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 46 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 45 | 11 |
| Tresiba Flextouch U-200 | Insulin Degludec | 45 | suppressed |
| Digoxin | Digoxin | 44 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 44 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 43 | suppressed |
| Aripiprazole | Aripiprazole | 42 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 42 | 11 |
| Synthroid | Levothyroxine Sodium | 42 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 42 | 19 |
| Gemfibrozil | Gemfibrozil | 41 | suppressed |
| Lovastatin | Lovastatin | 40 | suppressed |
| Valsartan | Valsartan | 39 | suppressed |
| Levofloxacin | Levofloxacin | 37 | 30 |
| Nystatin | Nystatin | 37 | 20 |
| Trulicity | Dulaglutide | 36 | suppressed |
| Azithromycin | Azithromycin | 35 | 27 |
| Oxycodone Hcl | Oxycodone Hcl | 35 | suppressed |
| Baclofen | Baclofen | 34 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 34 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 33 | suppressed |
| Acyclovir | Acyclovir | 30 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 30 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 30 | suppressed |
| Primidone | Primidone | 30 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 29 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 29 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 29 | suppressed |
| Lansoprazole | Lansoprazole | 29 | suppressed |
| Methotrexate | Methotrexate Sodium | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 12 |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Klor-Con M20 | Potassium Chloride | 27 | suppressed |
| Estradiol | Estradiol | 26 | suppressed |
| Eszopiclone | Eszopiclone | 26 | suppressed |
| Folic Acid | Folic Acid | 25 | suppressed |
| Glimepiride | Glimepiride | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Ramipril | Ramipril | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 24 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 23 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 23 | 15 |
| Torsemide | Torsemide | 23 | suppressed |
| Febuxostat | Febuxostat | 22 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 22 | suppressed |
| Repatha Syringe | Evolocumab | 22 | suppressed |
| Colchicine | Colchicine | 21 | suppressed |
| Methimazole | Methimazole | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 21 | suppressed |
| Vraylar | Cariprazine Hcl | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Dutasteride | Dutasteride | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Sotalol | Sotalol Hcl | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 14 |
| Levemir Flexpen | Insulin Detemir | 18 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 17 | suppressed |
| Cephalexin | Cephalexin | 17 | 12 |
| Cholestyramine Light | Cholestyramine | 17 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | 15 |
| Varenicline Tartrate | Varenicline Tartrate | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Modafinil | Modafinil | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Fentanyl | Fentanyl | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 15 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Qvar Redihaler | Beclomethasone Dipropionate | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 13 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Horizant | Gabapentin Enacarbil | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Famciclovir | Famciclovir | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Lyrica | Pregabalin | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 12 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Zaleplon | Zaleplon | 12 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 11 | suppressed |
| Edarbi | Azilsartan Medoxomil | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Insulin Aspart | Insulin Aspart | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,136.85 · 58 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AREXVY, BREZTRI, CAPLYTA, COMIRNATY, FARXIGA, GIVLAARI, JARDIANCE, MOUNJARO, Ozempic, PREVNAR 20, QULIPTA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, XYREM, XYWAV, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error